// App-Quantinova.ai

: CIRCULATING TUMOR CELL SUBTYPES AND BASELINE T-CELL POPULATION AS PROGNOSTIC BIOMARKERS TO COMBINATION THERAPY WITH CABOZANTINIB, NIVOLUMAB, AND IPILIMUMAB IN METASTATIC GENITOURINARY CANCER PATIENTS

Researchers

Presenter

  • Heather Chalfin

Principal Investigators

  • Scot Niglio

  • Joseph Schonhoft

  • Tiziano Pramparo

  • Adam Jendrisak

  • Lincy Chu

  • Jiyun Byun

  • Amanda Anderson

  • Yipeng Wang

  • Ryan Dittamore

  • Sumanta Pal

  • Primo Lara

  • Mark Stein

  • Seth Steinberg

  • Lisa Cordes

  • Lisa Ley

  • Marissa Mallek

  • Olena Sierra Ortiz

  • Rene Costello

  • Jacqueline Cadena

  • Carlos Diaz

  • Jane Trepel

  • Don Bottaro

  • Andrea Apolo

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 4

  • Cluster of differentiation 45

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • Cabozantinib

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02496208

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved